Skip to content
Skip to navigation menu

 

Latest Ventures

Cardiff University has an excellent track record of commercially exploiting the outcomes of its research. Forming a company to exploit University know-how or expertise is one of the routes available, and is managed through a close working relationship with Fusion IP. Licensing and royalty agreements, which enable businesses to use Cardiff research commercially, bring enormous benefits to a range of companies. Examples of recent highlights and successes are shown below along with current opportunities. If you are interested in obtaining further information please contact us.

 

Recent highlights

Could smell hold the key to ending pesticide use?
Scientists from the School of Chemistry and Rothamsted Research have, for the first time, created tiny molecules which mirror a natural occurring smell known to repel insects. The team hope that their research could provide a new way of designing and developing small smell molecules which would be otherwise be too difficult to produce by usual scientific and commercial methods.

IPCoP meets with more key companies
One of the aims of the IP Collaboration Project is to engage with key companies in key sectors, to promote easier access to university IP. IPCoP is pleased to be meeting with Tata and the Welsh Opto-Electronics Forum to explore new opportunities. The collaboration have previously met with Dwr Cymru Welsh Water, General Dynamics and IQE, amongst others.

High hopes for potential new asthma therapeutic
Cardiff scientists have identified the potential root cause of asthma and an existing drug that offers a new treatment. Published in April’s Science Translational Medicine journal, University researchers, working in collaboration with scientists at King's College London and the Mayo Clinic describe the previously unproven role of the calcium sensing receptor (CaSR) in causing asthma, a disease which affects 300 million people worldwide. Professor Riccardi and her collaborators are now seeking funding to determine the efficacy of calcilytic drugs in treating asthmas that are especially difficult to treat, particularly steroid-resistant and influenza-exacerbated asthma, and to test these drugs in patients with asthma.
https://www.youtube.com/watch?v=AzbfHW-UaO8&feature=youtu.be

Compass Mentis Exhibiting at ASME Conference
Compass Mentis, the diagnostic training programme created by Cardiff Medics will be exhibiting and presenting novel research, at the ASME Conference in July. The conference of the Association for the Study of Medical Education is one of the largest medical teaching conferences in the UK and will provide an ideal opportunity for demonstrating the system to Deans of Clinical Education from medical schools across the UK.

Joint IPCoP/OpenIQE Innovation Camp a sell-out
IPCoP and OpenIQE have brought together leading experts from Welsh universities, industry and government, for a collaborative workshop to address the challenges and opportunities in the priority areas of Healthcare & Bioscience, Energy, and Food supply and Agriculture. The sold-out event, held in Cardiff, was opened by presentations from leading sector experts, Innovate UK and Welsh Government.

Double Award for CM Diagnostics
Drs Chris Allender and Jenna Bowen were successful in securing investment from Innovate UK’s Launchpad in addition to a £3K win at the BioWales 2015 Dragon’s den event. In collaboration with University of Exeter under the GW4 alliance, CM Diagnostics will develop an innovative multiplexed platform based upon unique plasmonic effects conferred by gold-coated nanorods of different size as magnetic reporters.

Alesi Surgical secures £2.1m funding to drive commercialisation of Ultravision
Alesi Surgical (formerly Asalus Medical Instruments Limited) has secured additional funding of £2.1 million to drive the further commercialisation of its lead product, UltravisionTM, which was developed from concept to CE-marked device with backing from CPF, IP Group plc and Finance Wales.  In 2014, Ultravision was awarded a CE mark, and the company appointed distributors in 25 countries. The new investment provides capital to drive adoption of Ultravision, which has already been trialled across a spectrum of the most commonly performed laparoscopic procedures in gastrointestinal, gynaecological, urological and colorectal surgery. 

SynaptaJuice under trial by leading cell therapy developer
One of the UK’s leading developers of cell therapies has agreed terms for a commercial evaluation licence to work with neuronal differentiation technology developed in our School of Biosciences. The SynaptaJuice technology generates spontaneously firing neurons from induced pluripotent stem cells with significantly greater efficacy and speed than incumbent technologies.

Compass Mentis Exhibiting at C21 Conference
Compass Mentis, the device and training programme that teaches diagnostic reasoning to medical students, exhibited at the C21 Curriculum Conference held in Cardiff 0n 27th February. The Compass Mentis has already been well received by Cardiff University medical students and the project team plan to roll out the programme to other UK medical schools during 2015.

Agreement with SAGE Publications
SOCSI is contributing to one of SAGE commercial products, which will generate royalties and enhance the reach of methodologies developed in SOCSI. This has potential to enhance the reputation of the School and the University. This is the first time SAGE enters in such an agreement with a UK University and is a recognition of the high quality of research conducted in SOCSI.

 

Latest announcements

Novel Breast Cancer Agent Investment

Partnership with Tiziana Pharmaceuticals to support work on a novel anti-cancer agent 

Fusion IP Add New University Partners & Raise £20m

Share issue conditionally raises £20m for Fusion IP, who have agreed deals to work with Swansea University and the University of Nottingham

 

Spinout news

MedaPhor floats on AIM

MedaPhor group plc, a company spun out of research at Cardiff University, has today floated on the AIM market of the London Stock Exchange

Diurnal Announce Chronocort Phase II Success

Positive progress for Diurnal's CATCH (Chronocort® As Treatment for Congenital Adrenal Hyperplasia) clinical study

ENGIN Spin-Out Wins £650k DECC Funding

Fault Current Limited (“FCL”), has been awarded a £635,000 grant from the Department of Energy and Climate Change (DECC)

MedaPhor Spin-Out Enters Chinese Market

Exclusive distribution agreement with Tellyes Scientific Inc (“Tellyes”) to sell MedaPhor’s range of ultrasound simulators into mainland China

Asalus Records Clinical Trial Success

'First-In-Man' Trials Success for Ultravision™ Technology

 

 

 

For further information please contact the Technology Transfer Group